MarketPeel
Insider Trading Intelligence
PL

Patrick G. Lepore

VYNE
DIRECTOR · VYNE THERAPEUTICS INC. · CIK 0001055404
FILING MIX · LIFETIME100%/0%
BUYS
17
SELLS
0
TOTAL VALUE
$473.0K
COMPANIES
2
ACTIVE SINCE
May 2020
HOLDINGS NOW
142,605
AVG SELL PX
TRADE KIND
SHOWING 17 / 17
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Patrick G. Lepore, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+77.78%+5.86%+1.20%+4.66%+4.40%
14d9+66.67%+3.75%+1.97%+1.78%+1.45%
30d9+44.44%+1.71%+3.59%-1.88%-4.90%
60d9+22.22%-2.91%+3.62%-6.53%-27.92%
90d9+33.33%-17.21%+5.82%-23.03%-41.34%
180d9+22.22%-38.30%+9.99%-48.29%-56.44%
1y9+11.11%-61.02%+16.69%-77.72%-74.10%
2y9(1 pending)+0.00%-72.63%+21.01%-93.64%-89.31%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VYNE · 20,000 shares · as of Dec 12, 2025
015,62531,25046,87562,50020212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
FLOW · 17 buys / 0 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
20,00020,000Dec 12, 2025Dec 15, 2025View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
15,000$2.92$43.8K51,472Jan 15, 2025Jan 16, 2025View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
20,00020,000Dec 12, 2024Dec 13, 2024View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
20,00020,000Jan 1, 2024Jan 3, 2024View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
20,00020,000Dec 13, 2023Dec 15, 2023View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
13,000$3.91$50.8K36,472Nov 15, 2023Nov 17, 2023View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
20,000$2.48$49.7K23,472Mar 20, 2023Mar 22, 2023View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
20,50020,500Aug 10, 2022Aug 12, 2022View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
12,500$1.02$12.7K62,500Nov 30, 2021Dec 2, 2021View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
12,500$1.60$20.0K50,000Aug 25, 2021Aug 26, 2021View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
20,50020,500Jul 19, 2021Jul 20, 2021View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
12,500$3.60$45.0K37,500May 26, 2021May 27, 2021View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
12,500$7.41$92.6K25,000Mar 15, 2021Mar 16, 2021View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASE
50,000$1.71$85.4K50,000Dec 3, 2020Dec 7, 2020View →
MTNB
MATINAS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
122,605122,605Nov 2, 2020Nov 10, 2020View →
VYNE
VYNE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
45,00045,000Sep 10, 2020Sep 14, 2020View →
MTNB
MATINAS BIOPHARMA HOLDINGS, INC.
PURCHASE
100,000$0.73$73.0K400,000May 14, 2020May 18, 2020View →
Other insiders · VYNE
Loading peer insiders…
About this filer
CIK 0001055404
ROLE
Director
PRIMARY
VYNE
COMPANIES
2
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001055404DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback